These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 4070302)
1. The Antiepileptic Drug Development Program: an example of government-industry collaboration. White BG Prog Clin Biol Res; 1985; 197():83-93. PubMed ID: 4070302 [TBL] [Abstract][Full Text] [Related]
2. Antiepileptic drug development program. Porter RJ Prog Clin Biol Res; 1983; 127():53-66. PubMed ID: 6351101 [TBL] [Abstract][Full Text] [Related]
3. Advances in the clinical development of antiepileptic drugs. Porter RJ; Hessie BJ; Cereghino JJ; Gladding GD; Kupferberg HJ; Scoville B; White BG Fed Proc; 1985 Jul; 44(10):2645-9. PubMed ID: 3891417 [TBL] [Abstract][Full Text] [Related]
4. Large clinical trials in epilepsy: funding by the NIH versus pharmaceutical industry. Privitera M Epilepsy Res; 2006 Jan; 68(1):52-6. PubMed ID: 16377139 [TBL] [Abstract][Full Text] [Related]
5. The National Institutes of Health Small Business Innovation Research (SBIR) Program: opportunities for orphan drug development. Engstrom LO Prog Clin Biol Res; 1985; 197():25-30. PubMed ID: 4070295 [No Abstract] [Full Text] [Related]
6. The National Institutes of Health Anticonvulsant Drug Development Program: screening for efficacy. White HS; Wolf HH; Woodhead JH; Kupferberg HJ Adv Neurol; 1998; 76():29-39. PubMed ID: 9408461 [TBL] [Abstract][Full Text] [Related]
7. The National Cancer Institute's Drug Development Program. Schepartz SA Prog Clin Biol Res; 1985; 197():73-82. PubMed ID: 4070301 [No Abstract] [Full Text] [Related]
8. Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. Feuerstein GZ; Zaleska MM; Krams M; Wang X; Day M; Rutkowski JL; Finklestein SP; Pangalos MN; Poole M; Stiles GL; Ruffolo RR; Walsh FL J Cereb Blood Flow Metab; 2008 Jan; 28(1):217-9. PubMed ID: 17579658 [TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical industry screening for new antiepileptic drugs. Taylor CP; Marks JL Adv Neurol; 1998; 76():41-7. PubMed ID: 9408462 [TBL] [Abstract][Full Text] [Related]
10. Orphan products development and some methods for maximizing the usefulness of research on rare diseases. Finkel MJ Prog Clin Biol Res; 1985; 197():11-8. PubMed ID: 4070285 [No Abstract] [Full Text] [Related]
11. The clinical development of paclitaxel: a successful collaboration of academia, industry and the National Cancer Institute. Donehower RC Stem Cells; 1996 Jan; 14(1):25-8. PubMed ID: 8820947 [TBL] [Abstract][Full Text] [Related]
12. Anticancer Drug Development: The Way Forward. Connors T Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985 [TBL] [Abstract][Full Text] [Related]
13. Preclinical drug development in the antiepileptic drug development program. A cooperative effort of government and industry. Kupferberg HJ Prog Clin Biol Res; 1990; 361():113-30. PubMed ID: 2290840 [No Abstract] [Full Text] [Related]
14. Promoting, improving and accelerating the drug development and approval processes. Graul AI Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899 [TBL] [Abstract][Full Text] [Related]
15. The preclinical new drug research program of the National Cancer Institute. Driscoll JS Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438 [TBL] [Abstract][Full Text] [Related]
16. Understanding orphan drug regulations: an EU and U.S. comparative analysis. Grienenberger A J Biolaw Bus; 2004; 7(3):58-61. PubMed ID: 15460604 [TBL] [Abstract][Full Text] [Related]
17. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute. Christian MC; Pluda JM; Ho PT; Arbuck SG; Murgo AJ; Sausville EA Semin Oncol; 1997 Apr; 24(2):219-40. PubMed ID: 9129691 [TBL] [Abstract][Full Text] [Related]
19. Drug development for orphan diseases in the context of personalized medicine. Brewer GJ Transl Res; 2009 Dec; 154(6):314-22. PubMed ID: 19931198 [TBL] [Abstract][Full Text] [Related]
20. The role of voluntary disease organizations in research and development of orphan drugs. Horansky R Prog Clin Biol Res; 1985; 197():179-81. PubMed ID: 4070293 [No Abstract] [Full Text] [Related] [Next] [New Search]